Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.

Rodríguez-García, Alba; Giménez-Alejandre, Marta; Rojas, Juan J; Moreno, Rafael; Bazan-Peregrino, Miriam; Cascalló, Manel; Alemany, Ramon

Rodríguez-García, Alba; Giménez-Alejandre, Marta; Rojas, Juan J; Moreno, Rafael; Bazan-Peregrino, Miriam; Cascalló, Manel; Alemany, Ramon.

Affiliation

Rodríguez-García A; Translational Research Laboratory, IDIBELL-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Giménez-Alejandre M; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain.
Rojas JJ; Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
Moreno R; Translational Research Laboratory, IDIBELL-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Bazan-Peregrino M; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain.
Cascalló M; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain.
Alemany R; Translational Research Laboratory, IDIBELL-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain. ralemany@iconcologia.net.

Clin Cancer Res ; 21(6): 1406-18, 2015 Mar 15.

Article in En | MEDLINE | ID: mdl-25391696

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Oncolytic Virotherapy / Melanoma Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Document type: Article Affiliation country: España

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google